The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...

The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal ...

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and financial resilience in 2026.

Pharmacy benefit managers (PBMs) play a central but often invisible role in the prescription drug supply chain, influencing ...

The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...

Sagebrush Health Services has filed a lawsuit in California state court accusing Amgen of unlawfully cutting off 340B discounted drug sales to its Nevada clinics and reclaiming at least US$7,000,000 ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

Health Affairs' Rob Lott interviews Sayeh Nikpay of the University of Minnesota about her recent paper exploring how The Medicaid Drug Rebate Program and the 340B Program interact in ways that can ...

On January 15, 2026, President Trump released a one-page health policy framework. Among other things, the document includes ...

The cost of prescription drugs is certain to be a hot-button issue in the coming Illinois legislative session with two separate measures making for curious bedfellows in Springfield.